CanaQuest, which trades on the OTC Markets under the symbol “CANQF”, is a life science/pharmaceutical company focused on medical cannabis products, utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade). The Company is the industry partner with Dr. Steven Laviolette, a professor and neuroscientist at Western University, London, Ontario Canada. Dr. Laviolette is a scientific veteran with over 14 years of research experience in the field of mental health and cannabinoids, and he oversees a dedicated team of 13 scientists.
Dr. Laviolette has made two amazing discoveries:
1) Mentanine®, Omega-3 compounds + CBD isolate, non-psychotic formula (Provisional Patent filed) capable of acting on mental health issues inside the Central Nervous System “CNS” by crossing the Blood Brain Barrier (BBB), with a significant increase of efficacy, while reducing dosage and;
2) Mentabinol®, THC + L-Theanine formulation (International Patent filed) as a safer alternative to all other THC products, addressing anxiety, depression, schizophrenia and Post Traumatic Stress Disorder “PTSD”, while protecting all THC users from negative psychiatric side-effects caused by THC. The formulation is applicable for both medical and recreational consumption of THC.
Based on successful pre-clinical trial results, CanaQuest is planning to complete human trials and seek regulatory approval for Mentanine®Rx by applying for a Drug Identification Number (“DIN number”) with the US-based Food and Drug Administration (“FDA”) and Health Canada. The Company believes the FDA and Health Canada approval process will be significantly reduced because of the quality of the pre-clinical work and the recent regulatory approvals which have been provided for other products containing CBD and THC. Regulatory approvals will give CanaQuest the legal right to sell Rx products as approved drugs Over The Counter in pharmacies worldwide.
Mentanine® Pre-clinical trials:
- Indicated 10 times + the efficacy as compared to CBD molecules alone
- Reduced anxiety, depression, PTSD and addiction
- Showed a significant reduction of inflammation, which can be beneficial for pain management.
In 2019, the company won the Go Global Awards “Business of the Year – Category of Life Science”, presented by the International Trade Council.
CanaQuest’s wholly-owned subsidiary, ADC BioMedical Corp, was awarded a cannabis and cannabinoid products, Sales/Purchase, Import/Export license from Health Canada for Medical purposes.
CanaQuest has developed an e-commerce website as well at the following link: www.canaqueststore.com
Going global by perfecting the science of cannabinoids with the invention of new medical products & improving quality of life.
RESEARCH & DEVELOPMENT COLLABORATIONS
Dr. Laviolette has made two amazing discoveries: 1) Mentanine®, Omega3 compounds + CBD isolate; and 2) Mentabinol®, THC + L-Theanine formulation… treating mental health!
Western University has performed research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety, and schizophrenia.
Dr. Steven Laviolette, BSc, PhD
Addiction Research Group Dept. of Anatomy & Cell Biology
Dept. of Psychiatry
468 Medical Science Building
The Schulich School of Medicine, University of Western Ontario London, Ontario Canada N6A 5C1
The investigator leading the research is Dr. Steven Laviolette, a Professor and Neuroscientist in the Schulich School of Medicine & Dentistry at Western University in London, Ontario. Dr. Laviolette is a leader in the study of cannabinoids in mental health and was recently awarded “Faculty Scholar” status at Western University. Dr. Laviolette’s research team of 13 scientists has previously made numerous fundamental discoveries related to how cannabinoids impact and may serve as treatments for mental health disorders including schizophrenia, depression, post-traumatic stress disorder and anxiety. Dr. Laviolette’s primary research focus is in characterizing how specific phytochemical derivatives of cannabis may interact with specific brain pathways and molecular mechanisms whereby they may improve symptoms associated with various mental health disorders. Research from Dr. Laviolette’s team has been published in the top tier of neuroscience and psychiatry journals in the world.
Based on successful pre-clinical trial results, CanaQuest is planning to complete human trials and seek regulatory approval for Mentanine®Rx by applying for a Drug Identification Number “DIN number” with the US-based Food and Drug Administration (FDA) and Health Canada.
Dr. Laviolette stated, “Our CBD-based formulation works synergistically and has multiple times the efficacy compared to other CBD products on the market. This discovery sets the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects. There is strong evidence that this formulation is also a very promising epilepsy treatment, which I believe makes the formulation even more promising for these applications.”
The following is a link to Dr. Laviolette’s profile on the Western University website: